Treatment of non-alcoholic fatty liver disease: Can we already face the epidemic?

Acta Gastro-Enterologica Belgica

Volumn 76, Issue 2, 2013, Pages 200-209

  Verbeek, Jef ^a   Cassiman, David ^a   Lannoo, Matthias ^a   Laleman, Wim ^a   van der Merwe, Schalk ^a   Verslype, Chris ^a   Van Steenbergen, Werner ^a   Nevens, Frederik ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Clinical trials; NAFLD; NASH; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Treatment

Indexed keywords

ACTIVITIES OF DAILY LIVING; DISEASE MANAGEMENT; DISEASE PROGRESSION; FATTY LIVER; FOOD HABITS; HUMANS; LIFE STYLE; MORBIDITY; RISK FACTORS; WORLD HEALTH;

EID: 84886847070     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (108)

1. BRUNT E. Non-alcoholic fatty liver disease: what's new under the microscope? Gut, 2011, 60: 1152-1158.
2. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology, 2005, 42: 44-52.
3. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 2003, 37: 917-923.
4. Widhalm K., Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int. J. Obes. (Lond.), 2010, 34: 1451-1467.
5. de Alwis N.M., Day C.P. Non-alcoholic fatty liver disease: the mist gradually clears. J. Hepatol., 2008, 48: S104-112.
6. Soderberg C., Stal P., Askling J., Glaumann H., Lindberg G., Marmur J. et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology, 2010, 51: 595-602.
7. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 2006, 44: 865-873.
8. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology, 2005, 129: 113-121.
9. Targher G., Day C., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med., 2010, 363: 1341-1350.
10. Taki-Eldin A., Zhou L., Xie H.Y., Zheng S.S. Liver regeneration after liver transplantation. Eur. Surg. Res., 2012, 48: 139-153.
11. Day C.P. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology, 2005, 129: 375-378.
12. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E. et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology, 2005, 128: 1898.1906.
13. Merriman R.B., Ferrell L.D., Patti M.G., Weston S.R., Pabst M.S., Aouizerat B.E. et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology, 2006, 44: 874-880.
14. Wong V.W., Vergniol J., Wong G.L., Foucher J., Chan H.L., Le Bail B. et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology, 2010, 51: 454-462.
15. Martínez S.M., Crespo G., Navasa M., Forns X. Noninvasive assessment of liver fibrosis. Hepatology, 2011, 53: 325-335.
16. Angulo P., Keach J.C., Batts K.P., Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology, 1999, 30: 1356-1362.
17. Argo C.K., Northup P.G., Al-Osaimi A.M., Caldwell S.H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol., 2009, 51: 371-379.
18. Paradis V., Zalinski S., Chelbi E., Guedj N., Degos F., Vilgrain V. et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology, 2009, 49: 851-859.
19. Day C.P. From fat to inflammation. Gastroenterology, 2006, 130: 207-210.
20. Feldstein A.E. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin. Liver Dis., 2010, 30: 391-401.
21. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med., 2001, 344: 1343-1350.
22. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 2002, 346: 393-403.
23. Promrat K., Kleiner D., Niemeier H., Jackvony E., Kearns M., Wands J. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology, 2010, 51: 121-129.
24. St George A., Bauman A., Johnston A., Farrell G., Chey T., George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology, 2009, 50: 68-76.
25. Johnson N., Sachinwalla T., Walton D., Smith K., Armstrong A., Thompson M. et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology, 2009, 50: 1105-1112.
26. Kawaguchi T., Shiba N., Takano Y., Maeda T., Sata M. Hybrid training of voluntary and electrical muscle contractions decreased fasting blood glucose and serum interleukin-6 levels in elderly people: a pilot study. Appl. Physiol. Nutr. Metab., 2011, 36: 276-283.
27. Hallsworth K., Fattakhova G., Hollingsworth K., Thoma C., Moore S., Taylor R. et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut, 2011, 60: 1278-1283.
28. Johnson N., George J. Fitness versus fatness: Moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology, 2010, 52: 370-381.
29. Franz M., Van Wormer J., Crain A., Boucher J., Histon T., Caplan W. et al. Weight-loss outcomes: a systematic review and metaanalysis of weight-loss clinical trials with a minimum 1-year follow-up. J. Am. Diet. Assoc., 2007, 107: 1755-1767.
30. Kistler K.D., Brunt E.M., Clark J.M., Diehl A.M., Sallis J.F., Schwimmer J.B. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic Fatty liver disease. Am. J. Gastroenterol., 2011, 106: 460-468.
31. Donnelly J., Blair S., Jakicic J., Manore M., Rankin J., Smith B. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med. Sci. Sports Exerc., 2009, 41: 459-471.
32. Musso G., Gambino R., Cassader M., Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology, 2010, 52: 79-104.
33. Andersen T., Gluud C., Franzmann M., Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol., 1991, 12: 224-229.
34. Geerts A., Darius T., Chapelle T., Roeyen G., Francque S., Libbrecht L. et al. The multicenter Belgian survey on liver transplantation for hepatocellular failure after bariatric surgery. Transplant. Proc., 2010, 42: 4395-4398.
35. D'Albuquerque L., Gonzalez A., Wahle R., de Oliveira Souza E., Mancero J., de Oliveira e Silva A. Liver transplantation for subacute hepatocellular failure due to massive steatohepatitis after bariatric surgery. Liver Transpl., 2008, 14: 881-885.
36. Molendi-Coste O., Legry V., Leclercq I.A. Dietary lipids and NAFLD: suggestions for improved nutrition. Acta Gastroenterol. Belg., 2010, 73: 431-436.
37. Abdelmalek M., Suzuki A., Guy C., Unalp-Arida A., Colvin R., Johnson R. et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology, 2010, 51: 1961-1971.
38. Ouyang X., Cirillo P., Sautin Y., Mc Call S., Bruchette J.L., Diehl A.M. et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol., 2008, 48: 993-999.
39. Yilmaz Y. Review article: fructose in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther., 2012, 35: 1135-1144.
40. Lim J., Mietus-Snyder M., Valente A., Schwarz J., Lustig R. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat. Rev. Gastroenterol. Hepatol., 2010, 7: 251-264.
41. Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology, 2010, 51: 1972-1978.
42. Suzuki A., Angulo P., St Sauver J., Muto A., Okada T., Lindor K. Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am. J. Gastroenterol., 2007, 102: 1912-1919.
43. Catalano D., Martines G.F., Tonzuso A., Pirri C., Trovato F.M., Trovato G.M. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig. Dis. Sci., 2010, 55: 3200-3206.
44. Hamabe A., Uto H., Imamura Y., Kusano K., Mawatari S., Kumagai K. et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J. Gastroenterol., 2011.
45. Zein C.O., Unalp A., Colvin R., Liu Y.C., Mc Cullough A.J, Network NSCR. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J. Hepatol., 2011, 54: 753-759.
46. Chavez-Tapia N., Lizardi-Cervera J., Perez-Bautista O., Ramos-Ostos M., Uribe M. Smoking is not associated with nonalcoholic fatty liver disease. World J. Gastroenterol., 2006, 12: 5196-5200.
47. Haenle M., Brockmann S., Kron M., Bertling U., Mason R., Steinbach G. et al. Overweight, physical activity, tobacco and alcohol consumption in a cross-sectional random sample of German adults. BMC Public Health, 2006, 6: 233.
48. Mummadi R., Kasturi K., Chennareddygari S., Sood G. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol., 2008, 6: 1396-1402.
49. Chavez-Tapia N., Tellez-Avila F., Barrientos-Gutierrez T., Mendez-Sanchez N., Lizardi-Cervera J., Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst. Rev., 2010: CD007340.
50. Mathurin P., Hollebecque A., Arnalsteen L., Buob D., Leteurtre E., Caiazzo R. et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology, 2009, 137: 532-540.
51. Lassailly G., Caiazzo R., Buob D., Arnalsteen L., Louvet A., Colin M. et al. Bariatric surgery an efficient treatment for patients with steatohepatitis. J. Hepatol., 2012, 56, Supp 2, S6 Abstract 6.
52. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358: 893-894.
53. Uygun A., Kadayifci A., Isik A., Ozgurtas T., Deveci S., Tuzun A. et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther., 2004, 19: 537-544.
54. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N. et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol., 2005, 100: 1082-1090.
55. Haukeland J., Konopski Z., Eggesbø H., von Volkmann H., Raschpichler G., Bjøro K. et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand. J. Gastroenterol., 2009, 44: 853-860.
56. Belfort R., Harrison S., Brown K., Darland C., Finch J., Hardies J. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med., 2006, 355: 2297-2307.
57. Aithal G., Thomas J., Kaye P., Lawson A., Ryder S., Spendlove I. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008, 135: 1176-1184.
58. Sanyal A., Chalasani N., Kowdley K., Mc Cullough A., Diehl A., Bass N. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med., 2010, 362: 1675-1685.
59. Ratziu V., Giral P., Jacqueminet S., Charlotte F., Hartemann-Heurtier A., Serfaty L. et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology, 2008, 135: 100-110.
60. Ratziu V., Charlotte F., Bernhardt C., Giral P., Halbron M., Lenaour G. et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology, 2010, 51: 445-453.
61. Torres D.M., Jones F.J., Shaw J.C., Williams C.D., Ward J.A., Harrison S.A. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology, 2011, 54: 1631-1639.
62. Lutchman G., Modi A., Kleiner D., Promrat K., Heller T., Ghany M. et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology, 2007, 46: 424-429.
63. Rosen C.J. Revisiting the rosiglitazone story lessons learned. N. Engl. J. Med., 2010, 363: 803-806.
64. Ratziu V., de Ledinghen V., Oberti F., Mathurin P., Wartelle-Bladou C., Renou C. et al. FRESGUN obot. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J. Hepatol., 2010.
65. Laurin J., Lindor K., Crippin J., Gossard A., Gores G., Ludwig J. et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology, 1996, 23: 1464-1467.
66. Leuschner U., Lindenthal B., Herrmann G., Arnold J., Rössle M., Cordes H. et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology, 2010, 52: 472-479.
67. Lindor K., Kowdley K., Heathcote E., Harrison M., Jorgensen R., Angulo P. et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology, 2004, 39: 770-778.
68. Dufour J., Oneta C., Gonvers J., Bihl F., Cerny A., Cereda J. et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol., 2006, 4: 1537-1543.
69. Beraza N., Ofner-Ziegenfuss L., Ehedego H., Boekschoten M., Bischoff SC., Mueller M. et al. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut, 2011, 60: 387-396.
70. Georgescu E. Angiotensin receptor blockers in the treatment of NASH/ NAFLD: Could they be a first-class option? Adv. Ther., 2008, 25: 1141-1174.
71. Bataller R., Gabele E., Schoonhoven R., Morris T., Lehnert M., Yang L. et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and pro-inflammatory events in liver. Am. J. Physiol. Gastrointest. Liver Physiol., 2003, 285: G642-G651.
72. Pasarin M., La Mura V., Gracia-Sancho J., Garcia-Caldero H., Rodriguez-Vilarrupla A., Garcia-Pagan J. et al. Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS ONE, 2012, 7: e32785.
73. Pasarin M., Abraldes J., Rodriguez-Vilarrupla A., La Mura V., Garcia-Pagan J., Bosch J. Insulin resistance and liver microcirculation in a rat model of early NAFLD. J. Hepatol., 2011, 55: 1095-1102.
74. Francque S., Wamutu S., Chatterjee S., Van Marck E., Herman A., Ramon A. et al. Non-alcoholic steatohepatitis induces nonfibrosis-related portal hypertension associated with splanchnic vasodilatation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver Int., 2010, 30: 365-75.
75. Farrell G., Teoh N., Mc Cuskey R. Hepatic microcirculation in fatty liver disease. Anat. Rec., 291: 684-692.
76. DE CAVANAGH E., INSERRA F., FERDER L. Angiotensin II blockade: a strategy to slow aging by protecting mitochondria? Cardiovasc. Res., 2011, 89: 31-40.
77. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K. et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology, 2004, 40: 1222-1225.
78. Georgescu E., Ionescu R., Niculescu M., Mogoanta L., Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol., 2009, 15: 942-954.
79. Mallat A., Lotersztajn S. Endocannabinoids and their role in fatty liver disease. Dig. Dis., 2010, 28: 261-266.
80. Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endo cannabinoids in liver disease. Hepatology, 2011, 53: 346-355.
81. Després J., Ross R., Boka G., Alméras N., Lemieux I., Investigators A.-L. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler. Thromb. Vasc. Biol., 2009, 29: 416-423.
82. Topol E., Bousser M., Fox K., Creager M., Despres J., Easton J. et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet, 2010, 376: 517-523.
83. Harrison S., Torgerson S., Hayashi P., Ward J., Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2003, 98: 2485-2490.
84. Abdelmalek M., Sanderson S., Angulo P., Soldevila-Pico C., Liu C., Peter J. et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology, 2009, 50: 1818-1826.
85. Loguercio C., Federico A., Trappoliere M., Tuccillo C., de Sio I., Di Leva A. et al. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig. Dis. Sci., 2007, 52: 2387-2395.
86. Loguercio C., Andreone P., Brisc C., Brisc M.C., Bugianesi E., Chiaramonte M. et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic. Biol. Med., 2012.
87. Vilar Gomez E., Rodriguez De Miranda A., Gra Oramas B., Arus Soler E., Llanio Navarro R., Calzadilla Bertot L. et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther., 2009, 30: 999-1009.
88. Gonciarz M., Gonciarz Z., Bielanski W., Mularczyk A., Konturek P.C., Brzozowski T. et al. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin. J. Physiol. Pharmacol., 2010, 61: 705-710.
89. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R., Appel L., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med., 2005, 142: 37-46.
90. Harrison S., Fecht W., Brunt E., Neuschwander-Tetri B. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology, 2009, 49: 80-86.
91. Lee Y., Sutedja D., Wai C., Dan Y., Aung M., Zhou L. et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol. Int., 2008, 2: 196-201.
92. Satapathy S., Sakhuja P., Malhotra V., Sharma B., Sarin S. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol., 2007, 22: 634-638.
93. Zein C.O., Yerian L.M., Gogate P., Lopez R., Kirwan J.P., Feldstein A.E. et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology, 2011, 54: 1610-1619.
94. Malaguarnera M., Gargante M., Russo C., Antic T., Vacante M., Avitabile T. et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial. Am. J. Gastroenterol., 2010, 105: 1338-1345.
95. Musso G., Cassader M., Gambino R. Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr. Opin. Lipidol., 2011, 22: 489-496.
96. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H. et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin., 2008, 24: 275-286.
97. Valenti L., Moscatiello S., Vanni E., Fracanzani A.L., Bugianesi E., Fargion S. et al. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling - a propensity score-adjusted observational study. QJM, 2011, 104: 141-149.
98. Nakano T., Cheng Y.F., Lai C.Y., Hsu L.W., Chang Y.C., Deng J.Y. et al. Impact of artificial sunlight therapy on the progress of nonalcoholic fatty liver disease in rats. J. Hepatol., 2010.
99. Charlton M.R., Burns J.M., Pedersen R.A., Watt K.D., Heimbach J.K., Dierkhising R.A. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology, 2011, 141: 1249-1253.
100. Yalamanchili K., Saadeh S., Klintmalm G.B., Jennings L.W., Davis G.L. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl., 2010, 16: 431-439.
101. Malik S.M., deVera M.E., Fontes P., Shaikh O., Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am. J. Transplant., 2009, 9: 782-793.
102. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL, 2009 special conference. J. Hepatol., 2010, 53: 372-384.
103. Chalasani N., Younossi Z., Lavine J., Diehl A., Brunt E., Cusi K. et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology, 2012, 55: 2005-2023.
104. Baffy G., Brunt E., Caldwell S. Hepatocellular carcinoma in nonalcoholic fatty liver disease: An emerging menace. J. Hepatol., 2012, 56: 1384-1391.
105. EASL-EORTC Clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol., 2012, 56: 908-943.
106. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology, 2011, 53: 1020-2.
107. Vuppalanchi R., Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology, 2009, 49: 306-317.
108. Bellentani S., Dalle Grave R., Suppini A., Marchesini G., Network F.L.I. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology, 2008, 47: 746-754.